

1452



COPY OF PAPERS  
ORIGINALLY FILED

PATENT

Case Docket No. MVIEWM.005A

Date: March 5, 2002

Page 1

In re application of : Sherman, et al.  
App. No. : 09/501,730  
Filed : February 10, 2000  
For : AGGREGATE-FREE URATE  
OXIDASE FOR PREPARATION  
OF NON-IMMUNOGENIC  
POLYMER CONJUGATES  
Examiner : Pak, Yong D.  
Art Unit : 1652

) I hereby certify that this correspondence and all marked  
) attachments are being deposited with the United States  
) Postal Service as first class mail in an envelope addressed  
) to: United States Patent and Trademark Office, P.O. 2327,  
) Arlington, VA 22202, on

March 5, 2002

(Date)

*[Signature]*

Dale C. Hunt, Reg. No. 41,857

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE  
P.O. Box 2327  
Arlington, VA 22202

Sir:

Transmitted herewith is an Amendment in the above-identified application.

No fees are due as shown below:


CLAIMS AS FILED						
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims	23	—	33	= 0 ×	\$9	= \$0
Independent Claims	0	—	3	= 0 ×	\$42	= \$0
If application has been amended to contain multiple dependent claim(s), then add					\$140	= \$0
Time Extension Fee						\$0
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$0

Also enclosed is:

(X) Six (6) sheets of formal drawings.

(X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.

- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.



---

Dale C. Hunt

Registration No. 41,857

Attorney of Record



MVIEWSM.005A

# PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Sherman, <i>et al.</i>
Appl. No.	:	09/501,730
Filed	:	February 10, 2000
For	:	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON- IMMUNOGENIC POLYMER CONJUGATES
Examiner	:	Pak, Yong D.

) Group Art Unit 1652

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 2327, Arlington VA, 22202, on

March 5, 2002

(Date \_\_\_\_\_)

Dale C. Hunt, Reg. No. 41,857

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

## RESPONSE TO OFFICE ACTION

Assistant Commission of Patents  
United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action mailed December 5, 2001, in the above-captioned case, Applicants respectfully request consideration of the following remarks.

### Remarks

Claims 1-33 are currently pending, of which Claims 1-10, 17-28, and 33 are being examined and Claims 11-16 and 29-32 have been withdrawn without prejudice. Claims 1-10, 17-28, and 33 were rejected in the Office Action.

### Rejections under 35 U.S.C. §102(b)

## R&amp;D Focus News Reference

Claims 1-8, 17-28, and 33 are rejected under 35 U.S.C. §102(b) as being anticipated by R&D Focus Drug News of August 24, 1998. According to the Office Action, the R&D Focus News reference teaches a PEGylated recombinant uricase and “[b]ecause the referenced uricase